PubMed Health⌕ Search

Biomedical subjects

E Cesková

Publications and source records attributed to E Cesková.

At least 37 records · Page 2Linked to original sources
PubMed1993

[Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses].

In an open intraindividual comparison of haloperidol and oxyprothepine decanoates there was a tendency in favour of haloperidol decanoate. At the end of 9 months' maintenance treatment there were no statistically significant differences in the global BPRS score, CGI and individual BPRS items with exception of paranoidity. No differences in the occurrence of rehospitalizations and ambulatory relapses were found. As for side effects with haloperidol decanoate a higher occurrence of akathisia and a lower mean weigh increase (2 kg v. 4 kg) were observed and twice more pts had no side effects in comparison with oxyprothepine decanoate, but also these differences were not statistically significant. Taking into consideration the differences found (even if not statistically significant) and the individual reactivity, it seems to us advantageous to have a broader choice of depot neuroleptics.

Adult↗
PubMed1993

[Citalopram (Seropram) in tablet and infusion forms in the treatment of major depression].

Citalopram i.v. and oral had a reliable antidepressive and anxiolytic effect in 101 hospitalized patients, as apparent from the achievement of complete remission in cca 60% of the patients with major depression after four weeks follow-up. Treatment with citalopram by the intravenous or oral route was most successful in anxious or inhibitory depressions, while atypical forms with hypochondriac or obsedant features responded better to infusions. The global score of HAMD and FKD scales and typical symptoms of depression such as a pathic decreased mood, anhedonia, feelings of guilt, lack of interest, anxiety and suicidal thoughts were positively reduced. The following were not affected: loss of appetite, loss of weight, anosognosia, paranoidity, and hallucinations. The clinical onset of the therapeutic effect was on average apparent on the 10th-12th day of therapy, significantly sooner when the intravenous route was used. The authors did not find significant differences in the therapeutic results in patients under and above 60 years and in those with a mild or severe depression. As regards subjective preference and preference by relatives, infusions were unequivically preferred as they had, no doubt, also a psychological effect. As to the incidence of undesirable effects, the authors did not detect a difference between the two routes of administration of citalopram, which was well tolerated and 50% of the patients did not report any side-effects and the rare ones recorded were not more frequent than in 20% of patients.

Citalopram↗
PubMed1992

[Alternative therapy in the acute phase of endogenous depression--antiepileptics and new benzodiazepines and their comparison].

The average therapeutic effect of classical tricyclic antidepressants and antidepressants of the second and third generation varies between 60-70%. Moreover, tricycklic antidepressants are associated with undesirable effects mostly anticholinergic and "cardiotoxic", which may be a contraindication in particular in patients with multiple diseases and in older age groups. The authors compared two new alternative therapeutic procedures, represented by new highly effective benzodiazepines and anticonvulsants, as regards the therapeutic effect and side-effects. From this comparison ensues that their general therapeutic effect is on average comparable with the effect of tricyclic antidepressants, however, in the spectrum of their undesirable symptoms the anticholinergic effects are absent. Recent benzodiazepines have a better effect on depressions where anxiety and agitation are in the foreground. Their effect on depressive core symptoms is more marked, as compared with anticonvulsants. The most frequent side-effects are fatigue, somnolence and vertigo. Anticonvulsants have a balanced effect in different syndromological forms of depression. Undesirable effects are mostly gastrointestinal. In the authors' trials it did not lead to hypomania.

Acute Disease↗
PubMed1992

[The status of fluvoxamine among the antidepressive agents].

Fluvoxamine was administered in an open trial of 50 hospitalized patients with major depression of the melancholic type (DSM-III-R) for an average period of 24.56 days in mean minimal and maximal daily doses of 100-311 mg orally after a wash-out interval of 1-14 days. Treatment achieved complete improvement in 54% and partial improvement in 16% of the patients, significantly more frequently in women than in men. The antidepressant effect of fluvoxamine was confirmed also by a statistically significant reduction of the global HAMD and FKD score, starting on the 7th day of the trial. The therapeutic effect was clinically apparent during the second week of treatment. The best therapeutic effect was achieved in anxiety depressions (65%), to a lesser degree inhibitory depressions (50%) and atypical ones (46%), as apparent from the value of Náhunek's antidepressive index 0.88 which suggests a significant anxiolytic effectiveness of fluvoxamine. Fluvoxamine had a positive effect on the majority of HAMD and FKD items, incl. a depressive mood, anxiety, feelings of guilt, anhedonia, reduced interest and ability, obsession, depressive thoughts and suicidal tendencies. Reduced motor activity, loss of appetite, insight, somatic symptoms, paranoidity and hypochondria were less influenced. At the onset of treatment the preparation did not reduced insomnia and thus in 72% patients hypnotics were added. In the course of fluvoxamine therapy no suicidal attempts were observed although 34 (68%) of the patients initially admitted had suicidal thoughts. Fluvoxamine is well tolerated by patients; as to side-effects gastrointestinal complaints were most frequent (in 28% of the patients).

Adult↗
PubMed1990

[Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].

In a three-week crossover controlled the authors administered alternately sulpiride and perphenazine with an intermittent placebo interval, to 40 hospitalized patients with acute exacerbation of schizophrenic and schizoaffective psychosis. According to evaluation recommended by Serejský significantly more complete remissions type AB were achieved especially in schizodepressive patients given sulpiride. The global score of BPRS and FKP scales after administration of the two tested neuroleptic drugs differed: sulpiride had a more favourable effect on depression, emotional withdrawal, reduced affectivity, slower motor activity, worry about the somatic state and hallucinations, while perphenazine gave better results in patients with reduced compliance, lack of cooperation, hostility and excitation. Sulpiride is well tolerated by the patients. Pharmacological parkinsonoid was observed only in cca half the patients, as compared with perphenazine and therefore also the need of correction by antiparkinsonian drugs was significantly smalled. The low incidence of extrapyramidal, hypnosedative and autonomous undesirable effects gave sulpiride the optimal position in our classification of 16 tested neuroleptic drugs. In one third of the patients no undesirable side--effects were observed.

Adolescent↗